Literature DB >> 23574315

Immunological biomarkers: catalysts for translational advances in autoimmune diabetes.

S T Ahmed1, E Akirav, E Bradshaw, J Buckner, E McKinney, F J Quintana, F Waldron-Lynch, J Nepom.   

Abstract

In a recent workshop organized by the JDRF focused on the 'Identification and Utilization of Robust Biomarkers in Type1 Diabetes', leaders in the field of type 1 diabetes (T1D)/autoimmunity and assay technology came together from academia, government and industry to assess the current state of the field, evaluate available resources/technologies and identify gaps that need to be filled for moving the field of T1D research forward. The highlights of this workshop are discussed in this paper, as well as the proposal for a larger, planned consortium effort, incorporating a JDRF Biomarker Core, to foster collaboration and accelerate progress in this critically needed area of T1D research.
© 2013 British Society for Immunology.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23574315      PMCID： PMC3628321          DOI： 10.1111/cei.12063

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  40 in total

Review 1.  Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes.

Authors:  Bart O Roep; Mark Peakman
Journal:  Nat Rev Immunol       Date:  2010-02       Impact factor: 53.106

2.  Nucleic acid programmable protein array a just-in-time multiplexed protein expression and purification platform.

Authors:  Ji Qiu; Joshua LaBaer
Journal:  Methods Enzymol       Date:  2011       Impact factor: 1.600

3.  Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse.

Authors:  Frances Crawford; Brian Stadinski; Niyun Jin; Aaron Michels; Maki Nakayama; Philip Pratt; Philippa Marrack; George Eisenbarth; John W Kappler
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

4.  Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes.

Authors:  Evan W Newell; Natalia Sigal; Sean C Bendall; Garry P Nolan; Mark M Davis
Journal:  Immunity       Date:  2012-01-27       Impact factor: 31.745

5.  Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients.

Authors:  Jason L Gaglia; Alexander R Guimaraes; Mukesh Harisinghani; Stuart E Turvey; Richard Jackson; Christophe Benoist; Diane Mathis; Ralph Weissleder
Journal:  J Clin Invest       Date:  2010-12-01       Impact factor: 14.808

6.  CD8 T cell autoreactivity to preproinsulin epitopes with very low human leucocyte antigen class I binding affinity.

Authors:  J R F Abreu; S Martina; A A Verrijn Stuart; Y E Fillié; K L M C Franken; J W Drijfhout; B O Roep
Journal:  Clin Exp Immunol       Date:  2012-10       Impact factor: 4.330

Review 7.  Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society.

Authors:  R Mallone; S I Mannering; B M Brooks-Worrell; I Durinovic-Belló; C M Cilio; F S Wong; N C Schloot
Journal:  Clin Exp Immunol       Date:  2010-10-05       Impact factor: 4.330

8.  A CD8+ T cell transcription signature predicts prognosis in autoimmune disease.

Authors:  Eoin F McKinney; Paul A Lyons; Edward J Carr; Jane L Hollis; David R W Jayne; Lisa C Willcocks; Maria Koukoulaki; Alvis Brazma; Vojislav Jovanovic; D Michael Kemeny; Andrew J Pollard; Paul A Macary; Afzal N Chaudhry; Kenneth G C Smith
Journal:  Nat Med       Date:  2010-04-18       Impact factor: 53.440

9.  Transcriptional signatures as a disease-specific and predictive inflammatory biomarker for type 1 diabetes.

Authors:  H Levy; X Wang; M Kaldunski; S Jia; J Kramer; S J Pavletich; M Reske; T Gessel; M Yassai; M W Quasney; M K Dahmer; J Gorski; M J Hessner
Journal:  Genes Immun       Date:  2012-09-13       Impact factor: 2.676

10.  Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.

Authors:  S Alice Long; Karen Cerosaletti; Paul L Bollyky; Megan Tatum; Heather Shilling; Sheng Zhang; Zhong-Yin Zhang; Catherine Pihoker; Srinath Sanda; Carla Greenbaum; Jane H Buckner
Journal:  Diabetes       Date:  2009-10-29       Impact factor: 9.461
View more
  3 in total

Review 1.  Progress in immune-based therapies for type 1 diabetes.

Authors:  M von Herrath; M Peakman; B Roep
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

2.  Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).

Authors:  James Heywood; Marina Evangelou; Donna Goymer; Jane Kennet; Katerina Anselmiova; Catherine Guy; Criona O'Brien; Sarah Nutland; Judy Brown; Neil M Walker; John A Todd; Frank Waldron-Lynch
Journal:  Trials       Date:  2015-03-11       Impact factor: 2.279

Review 3.  Evaluation of Candidate Biomarkers of Type 1 Diabetes via the Core for Assay Validation.

Authors:  Cate Speake; Jared M Odegard
Journal:  Biomark Insights       Date:  2015-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.